ReviewCurrent opinion in rheumatology2022
Anti-MDA5 dermatomyositis: an update from bench to bedside.
Review in Current opinion in rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- How loss-of-function mutations inJournal of translational autoimmunity · 2026Review
- Case Report: Lung transplantation for rare anti-MDA5-positive rapidly progressive interstitial lung disease: two cases and a narrative review.Frontiers in immunology · 2026Review
- A transfer learning-based multimodal model for early prediction of 90-day respiratory failure in dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- Prognostic factors and a nomogram for survival in anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease.BMC pulmonary medicine · 2025Article
- Dermatomyositis and microscopic polyangiitis overlap: a case-based review.Rheumatology international · 2025Review
- Article
- Clinical Features of Dermatomyositis Associated with Myositis-Specific Antibodies in Moroccan Patients.Clinics and practice · 2025Article
- Anti-MDA5 Positive Dermatomyositis Overlapping with Rheumatoid Arthritis: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case report.Frontiers in immunology · 2025Article
- Dactylitis in Melanoma Differentiation-Associated protein 5 (MDA5)-associated amyopathic dermatomyositis: clue or conundrum?Clinical rheumatology · 2025Article
- Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.Clinical rheumatology · 2025Article
- Different faces of anti-melanoma differentiation-associated gene 5 antibody-positive myositis.Reumatologia · 2025Article
- Pneumomediastinum in MDA5+ Dermatomyositis: A Case Series.Mediterranean journal of rheumatology · 2024Article
- Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering.Frontiers in immunology · 2024Article
- Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies.Diagnostics (Basel, Switzerland) · 2023Article
- Spontaneous intramuscular hemorrhage in cancer-associated dermatomyositis: a case and literature review.BMC musculoskeletal disorders · 2023Review
- Interferon and autoantigens: intersection in autoimmunity.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes the recent developments about anti-MDA5 antibody positive dermatomyositis with a focus on its pathogenesis, clinical features and treatment options of rapidly progressive interstitial lung disease, its most ominous complication. RECENT
findingsAnti-MDA5+ dermatomyositis has a heterogeneous clinical spectrum with different patient subsets exhibiting widely different outcomes; severe acute interstitial lung disease is the main factor impacting prognosis. The pathogenetic role of anti-MDA5 antibodies is an active area of investigation. SUMMARY: Anti-MDA5+ dermatomyositis has a wider spectrum of manifestations than previously thought. A high index of suspicion is needed not to miss atypical presentations. In the setting of acute interstitial lung involvement, once a confident diagnosis is made, an aggressive approach with early combined immunosuppression affords the best chances of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.